View Older Stories View More Recent Stories

Jun 6, 2022 06:26AM H.C. Wainwright Reiterates Buy Rating, $6 Price Target on Caladrius Biosciences (CLBS)
Jun 6, 2022 06:24AM Batiraxcept has "Best in Class Potential" - H.C. Wainwright Reiterates Buy Rating on Aravive (ARAV) with $26 Price Target
Jun 6, 2022 06:20AM Eli Lilly's (LLY) Latest Mounjaro Efficacy Data "Unmatched", Analyst Sees More Upside, Reiterates Stock as Top Pick - Mizuho Securities Bullish with $365 Price Target
Jun 6, 2022 06:16AM Gilead Updates "Bode Well for SL-172154 " - H.C. Wainwright Reiterates Buy Rating, $28 Price Target on Shattuck Labs (STTK)
Jun 6, 2022 06:14AM "Continue to Expect Krystexxa Label Expansion" - Oppenheimer Horizon Therapeutics (HZNP) at Outperform with $140 Price Target
Jun 6, 2022 06:12AM "NEON-1 and NEON-2 Continue to Shine" - H.C. Wainwright Bullish on Alpine Immune Sciences (ALPN) With Buy Rating, $21 Price Target
Jun 6, 2022 06:10AM H.C. Wainwright Reiterates Buy Rating, $16 Price Target on Biomea Fusion Inc. (BMEA)
Jun 6, 2022 06:09AM PRAX-114 Has "Good Probability of Success and Upside" - Cowen Bullish on Praxis Precision Medicines (PRAX) Ahead of Upcoming Data Readout
Jun 6, 2022 06:07AM "Zota is Work in Progress", Focus Remains on Tomi - Stifel Maintains eFFECTOR Therapeutics (EFTR) at Hold
Jun 6, 2022 05:57AM "Continue to Expect Increased Uptake of Vonjo" - Needham & Company Reiterates Buy Rating on CTI BioPharma (CTIC) with $8 Price Target
Jun 6, 2022 05:55AM "Upcoming Data Announcement Could Support Outperformance" - Oppenheimer Bullish on NuCana (NCNA) with Outperform Rating and $5 Price Target
Jun 3, 2022 05:24PM Stifel Reiterates Buy Rating on Mirati Therapeutics (MRTX) Ahead of MRTX's Upcoming Brain Data
Jun 2, 2022 09:00AM Truist Securities Reiterates Buy Rating, $718 Price Target on Regeneron Pharma (REGN) Despite Biogen's (BIIB) Byooviz Launch
Jun 2, 2022 08:44AM Cantor Fitzgerald Reiterates Overweight Rating, $34 Price Target on Nyxoah SA (NYXH)
Jun 2, 2022 07:23AM Clene, Inc. (CLNN) PT Lowered to $16 at Oppenheimer, "Outperform" Rating Maintained, New CNM-Au8 Data "Support Candidate's Potential"
Jun 2, 2022 06:57AM Moderna (MRNA) Sliding Lower as EU Postpones Additional COVID Booster Deliveries, Pfizer (PFE) and Novavax (NVAX) on Watch
Jun 2, 2022 06:09AM H.C. Wainwright Reiterates Buy Rating, $25 Price Target on Atreca (BCEL) on Reorganization Efforts
Jun 2, 2022 06:04AM H.C. Wainwright Assumes Biomea Fusion (BMEA) at Buy with $16 Price Target
Jun 2, 2022 05:56AM Oppenheimer Reiterates Outperform Rating, $17 Price Target on Alpine Immune Sciences (ALPN)
Jun 2, 2022 05:55AM Repare Therapeutics (RPTX) PT Raised to $13 at Stifel, "Deal With Roche is Great for RTPX"
Jun 1, 2022 11:18AM Raymond James Reiterates Market Perform Rating on Sage Therapeutics (SAGE), Sees Limited Upside to Stock Despite Strong zuranolone Data
Jun 1, 2022 10:10AM Tonix Pharmaceuticals (TNXP) Soars on Monkeypox Vaccine Patent, TNX-801 Could be an 'Effective and Better Tolerated' Vaccine According to Analyst
Jun 1, 2022 09:07AM Stifel Reiterates Buy Rating, $105 Price Target on Mirati Therapeutics (MRTX)
Jun 1, 2022 09:00AM Cowen Reiterates Outperform Rating on Axsome Therapeutics (AXSM), Analyst Remains Optimistic for Approval of AXS-05, Sees 100-125% Upside
Jun 1, 2022 07:54AM UPDATE: CORRECTION: Stifel Reiterates Buy Rating on SAGE Therapeutics (SAGE), "Approvability of zuranolone in MDD" Remains Key Question
Jun 1, 2022 06:53AM Biotechs Trade at a "Very Attractive Discount", Set for "Outperformance in 2022" - Analyst Defends Biotechnology Sector in the Face of Weakness
May 27, 2022 06:35AM UPDATE: Cantor Fitzgerald Assumes Aziyo Biologics Inc. (AZYO) at Overweight, PT Lowered to $12
May 27, 2022 06:15AM Mirati Therapeutics (MRTX) PT Lowered to $105 at Stifel, Buy Rating Maintained, "Negative After-Market Move is Overdone"
May 27, 2022 06:14AM Iovanace Biotherapeutics (IOVA) PT Lowered to $13 at Stifel, Buy Rating Maintained, "Stock Reaction Seems Overdone"
May 27, 2022 06:07AM Stifel Reiterates Buy Rating, $43 Price Target on Fulcrum Therapeutics (FULC)
May 27, 2022 06:06AM Iovanace Biotherapeutics (IOVA) PT Lowered to $27 at Oppenheimer on Disappointing lifileucel Data, Reiterated at Buy
May 26, 2022 07:33AM "PH94B Could Become First Rapid-Onset Treatment for SAD" - William Blair Reiterates Outperform Rating on VistaGen Therapeutics (VTGN)
May 26, 2022 05:47AM "Near Term Focus Remains on Upcoming Schizophrenia Data; Risk/Reward Remains Compelling" - Mizuho Securities Reiterates Karuna Therapeutics (KRTX) at Buy with $15 Price Target
May 26, 2022 05:43AM Stifel Reiterates Buy Rating, $15 Price Target on Alphatec Holdings (ATEC)
May 25, 2022 02:33PM "Weakness is Buying Opportunity, Clinical Programs Remain Underappreciated by Investors" - Arcutis Biotherapeutics (ARQT) Defended at Mizuho Securities, Buy Rating and $57 Price Target Reiterated
May 25, 2022 12:07PM Citius Pharmaceuticals (CTXR) Reiterated at Buy by Dawson James on I/ONTAK Spinoff, $10 Price Target Maintained
May 25, 2022 11:33AM Phathom Pharmaceuticals (PHAT) PT Lowered to $44 at Needham & Company to Reflect vonoprazan Launch Dynamic, "Remain Confident in the Commercial Potential"
May 25, 2022 11:26AM Needham & Company Downgrades Verrica Pharmaceuticals (VRCA) to Hold, Removes Price Target on "Uncertain Delay", Reiterates that "Ycanth Has a Bright Commercial Future"
May 25, 2022 11:05AM Stifel Reiterates Buy Rating on Karuna Therapeutics Inc. (KRTX)
May 25, 2022 10:02AM Dawson James Maintains Brainstorm Cell Therapeutics (BCLI) at Neutral, "NurOwn Efficacy, At Best, is Minimal"
May 25, 2022 05:59AM "Continue to See Vtama’s Profile as Truly Differentiated" - Truist Securities Bullish on Roivant Sciences (ROIV) with $15 Price Target
May 25, 2022 05:57AM Cabaletta Bio (CABA) PT Lowered to $10 at Mizuho Securities to "Reflect Current Economic Environment", But Rating Maintained
May 24, 2022 08:21AM "VTAMA Has Blockbuster Potential" - Cantor Fitzgerald Bullish on Roivant Sciences (ROIV) Following Dermavant’s Drug Approval
May 24, 2022 07:47AM United Therapeutics (UTHR): Tyvaso DPI Approval and Label is 'Best Case Scenario', Brings 'Greater Pipeline Value' and 'Slower Market Share Erosion'
May 24, 2022 06:16AM Approved Tyvaso DPI Label is "Best Case Scenario" - Cowen Bullish on United Therapeutics (UTHR) Following FDA Approval
May 24, 2022 06:14AM Liquidia Technologies (LQDA) Defended by Needham & Company Despite Tyvaso DPI Approval, Cites "Significant Potential of Yutrepia"
May 24, 2022 06:10AM Stifel Reiterates Buy Rating, $10 Price Target on Apollo Endosurgery (APEN)
May 23, 2022 03:19PM "Approval of Tyvaso DPI Marks Significant Inflection Point", Shares Present "Upside From Current Levels" - Cantor Fitzgerald Bullish on MannKind (MNKD) with $6.50 Price Target
May 23, 2022 09:31AM Electronic Arts (EA) Said Actively Pursuing Sale or Merger, Comcast and Amazon Among Potential Suitors; Stock Now 'Likely Has a Floor' Analyst Says
May 23, 2022 05:57AM Management Changes and Rising Short Interest Mean "Upside Could be Accentuated" - Oppenheimer Bullish on Veru (VERU) with $36 Price Target
View More Recent Stories View Older Stories